Abstract
In the period of development of new drugs every day intended with a fast and effective therapeutic action, the risk of chance of adverse drug reaction is also increasing more. The number of subjects which are involved in the clinical trial phases cannot be generalized or extrapolated to the entire population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
